ESMO 2022 Conference Coverage


 

ESMO 2022 on Primary Endpoint Results of the Randomized Phase 2 SYNERGY Trial: 1L Chemo-IO of Durvalumab, Paclitaxel, and Carboplatin +/- Anti-CD73 Antibody Oleclumab in Advanced or Metastatic TNBC

82 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login